Findings

What do systematic reviews say?

807 questions · 849 findings · 68 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 236 · 27.8%GRADE not reported 50 · 5.9%Very low 266 · 31.3%Low 168 · 19.8%Moderate 104 · 12.2%High 25 · 2.9%

Pantoprazole in higher doses (1.2 mg/kg) vs pantoprazole at lower doses (0.3 mg/kg)

Adverse events · GORD in children over 1 year of age

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Very low

Pantoprazole in higher doses (1.2 mg/kg) vs pantoprazole at lower doses (0.3 mg/kg)

Improvement in pH indices ‐ not measured · GORD in children over 1 year of age

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Omeprazole vs placebo

Adverse events ‐ not reported · GORD in infants

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pantoprazole in higher doses (1.2 mg/kg) vs pantoprazole at lower doses (0.3 mg/kg)

Endoscopic metrics ‐ not measured · GORD in children over 1 year of age

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Omeprazole vs placebo

Improvement in pH metrics in infants · GORD in infants

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Very low

Omeprazole vs placebo

Endoscopic metrics ‐ not measured · GORD in infants

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Omeprazole vs ranitidine

Improvement in symptoms in infants · GORD in infants

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Very low

Omeprazole vs ranitidine

Adverse events in infants ‐ not measured · GORD in infants

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Omeprazole vs ranitidine

Improvement in pH metrics in infants ‐ not measured · GORD in infants

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Omeprazole vs ranitidine

Improvement in endoscopic findings in infants ‐ not measured · GORD in infants

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Esomeprazole vs placebo

Improvement in symptoms and signs in infants · GORD in infants

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 52 participants
Very low

Carbonic anhydrase inhibitors vs inactive control

cAHI · adults with central sleep apnoea associated with heart failure

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Very low

Anxiolytics vs inactive control

Cardiovascular mortality · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anxiolytics vs inactive control

Serious adverse events · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anxiolytics vs inactive control

Quality of sleep · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anxiolytics vs inactive control

Quality of lifeÂ · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anxiolytics vs inactive control

AHI · adults with central sleep apnoea associated with heart failure

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
GRADE not reported

Anxiolytics vs inactive control

All‐cause mortality · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Methylxanthine derivatives vs inactive control

cAHI · adults with central sleep apnoea associated with heart failure

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 15 participants
Very low

Methylxanthine derivatives vs inactive control

Cardiovascular mortality · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found